Latest Breaking News On - Elpiscience biopharma ltd - Page 1 : vimarsana.com

Compass Therapeutics, Inc (CMPX) Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models

Compass Therapeutics, Inc (CMPX) Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSan diego convention centerThomas schuetzHandok incElpiscience biopharma ltdResearch development at compassAmerican association for cancer researchPresentations of the companyCompass therapeutics incCompass therapeuticsCancer researchAnnual meetingCheckpoint inhibitorElpiscience biopharma

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSan diego convention centerThomas schuetzDanna giffordExchange commissionHandok incAmerican association for cancer researchResearch development at compassCompass therapeutics incPresentations of the companyElpiscience biopharma ltdSenior communications managerCompass therapeuticscompass therapeutics incCancer researchAnnual meeting

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Major Histocompatibility Complex Class I negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of.

United statesSan diego convention centerSan diegoThomas schuetzDanna giffordSenior communicationsAmerican association for cancer researchCompass therapeutics incResearch development at compassPresentations of the companyExchange commissionElpiscience biopharma ltdHandok incGlobenewswire incCancer researchAnnual meeting

Following JPM, 2024 outlook ranges from hopeful to cautious

Setting the tone for the biopharma industry as it enters a new year, the J.P. Morgan Healthcare Conference (JPM) held each January has once again led to reflections, projections and earnest hopes for improving financial and M&A markets. Despite concerns over valuations, raising money and pricing issues, industry leaders are generally upbeat as the industry moves into 2024. JPM’s Sophie Jones, managing director of health care investment banking, noted in a Jan. 18 webinar sponsored by the Biotechnology Innovation Organization that the conference included more than 700 companies. “It’s morphing now into really the kickoff into everybody’s year.”

Sophie jonesBiotechnology innovation organizationHealthcare conferenceElpiscience biopharma ltdParatek pharmaceuticals incJp morgan healthcare conferenceDeals andm amp a

Elpiscience out-licenses preclinical bispecific macrophage engagers to Astellas in deal worth up to $1 7B

Elpiscience Biopharma Ltd. is out-licensing to Astellas Pharma Inc. two preclinical bispecific macrophage engagers – ES-019, an anti-PD-L1/SIRPα bispecific antibody, and another unnamed program – in a deal worth up to $1.7 billion. The deal marks the Shanghai-based company’s first out-licensing deal, Elpiscience CEO Darren Ji told BioWorld, noting that Astellas will have global rights to both molecules with a potential to in-license two more.

Darren jiAstellas pharma incElpiscience biopharma ltdElpiscience biopharmaAstellas pharmaAstellas pharma incElpiscience biopharma ltdBispecific macrophage engagersEs 019Pd l1